Cargando…
Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease
BACKGROUND: Somatostatin (SST) inhibits intracellular cyclic adenosine monophosphate (cAMP) production and thus may modify cyst formation in autosomal dominant polycystic kidney disease (ADPKD). We investigated whether endogenous plasma SST concentration is associated with disease severity and progr...
Autores principales: | Messchendorp, A. Lianne, Spithoven, Edwin M., Casteleijn, Niek F., Dam, Wendy A., van den Born, Jacob, Tonnis, Wouter F., Gaillard, Carlo A. J. M., Meijer, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299932/ https://www.ncbi.nlm.nih.gov/pubmed/30567514 http://dx.doi.org/10.1186/s12882-018-1176-y |
Ejemplares similares
-
Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
por: Messchendorp, A Lianne, et al.
Publicado: (2019) -
Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression
por: Messchendorp, A. Lianne, et al.
Publicado: (2017) -
Nephrectomy in Autosomal Dominant Polycystic Kidney Disease: A Patient with Exceptionally Large, Still Functioning Kidneys
por: Spithoven, Edwin M., et al.
Publicado: (2014) -
Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study
por: Lantinga, Marten A., et al.
Publicado: (2016) -
Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD
por: Messchendorp, A. Lianne, et al.
Publicado: (2019)